Viral Pathogenesis of Early Cystic Fibrosis Lung Disease

N/ACompletedNCT01973192

Indiana University65 enrolled

Overview

The purpose of this study is to test the hypothesis that early viral infections alter the bacterial flora and inflammatory profile in the airway and accelerate progression of pulmonary disease in infants with cystic fibrosis.

The proposed study is a unique international collaboration between three large CF research centers. This proposal will determine the impact of early respiratory viral infections on bacterial flora and inflammatory profiles in the CF airway as well as the impact of these pathogens on clinical, physiologic and structural markers of disease.The proposed study is designed to follow infants diagnosed with CF through newborn screening to determine the effect of viral infections on the lower airway microbiome, clinical symptoms, pulmonary function and structural changes during the first year of life. The proposed study will measure lower airway inflammation and infection using BAL, oral swabs, and nasal swabs; outcomes will be assessed through infant lung function testing, computerized tomography scans of the chest, and pulmonary exacerbation rate.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Cystic Fibrosis

Eligibility

Sex: ALLMin age: 2 MonthsMax age: 4 Months

Medical Language ↔ Plain English

Inclusion Criteria: 1. Diagnosis of CF by newborn screening, at least one clinical feature of CF, and documented sweat chloride greater than 60 mEq/L by quantitative pilocarpine iontophoresis or compatible genotype with two identifiable mutant CFTR alleles. 2. Less than 4 months of age at Screening Visit 3. Ability to comply with study visits and study procedures as judged by site investigator. Exclusion Criteria: 1. Intercurrent respiratory illness, defined as increase in cough, wheezing, or respiratory rate with onset 14 days before iPFT-bronchoscopy visit. 2. Measured hemoglobin oxygen saturation less than 95% during the iPFT-bronchoscopy visit. 3. History of adverse reaction to sedation. 4. Clinically significant upper airway obstruction as determined by the site investigator. 5. Severe gastroesophageal reflux, defined as persistent frequent emesis despite therapy. 6. Major organ dysfunction, not including pancreatic dysfunction. 7. Physical findings that would compromise the safety of the subject or the quality of the study data as determined by site investigator.

Locations (4)

Riley Hospital for Children at Indiana University Health

Indianapolis, Indiana, United States

St. Louis Children's Hospital

St Louis, Missouri, United States

The Royal Children's Hospital

Melbourne, Victoria, Australia

Telethon Kids Institute

West Perth, Australia

Outcomes

Primary Outcomes

Viral infection

To determine the effect(s) of viral infections on the evolution of endobronchial bacterial infection and inflammation in CF infants.

Time frame: 12 months

Secondary Outcomes

Pulmonary exacerbation rate

To identify the impact of respiratory viruses on the onset, frequency, and duration of respiratory symptoms in CF infants diagnosed through newborn screening.

Time frame: 12 Months

Forced Expiratory Volume

To assess development of early lung disease as defined through physiological measures of forced expiratory flows, lung volumes, and ventilation inhomogeneity in CF infants.

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.